Ordering Recommendation

Diagnostic and predictive testing for multiple endocrine neoplasia type 2 (MEN2) syndrome caused by pathogenic variants in the RET gene.

Methodology

Massively Parallel Sequencing

Performed

Varies

Reported

10-15 days

New York DOH Approval Status

Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.

Specimen Required

Patient Preparation
Collect

Lavender or pink (EDTA) or yellow (ACD solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 2 mL)

Storage/Transport Temperature
Unacceptable Conditions

Serum or plasma; grossly hemolyzed or frozen specimens; saliva, buccal brush, or swab; FFPE tissue.

Remarks
Stability

Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: Unacceptable

Reference Interval

By report

Interpretive Data

Refer to report.

Compliance Category

Laboratory Developed Test (LDT)

Note

Gene Tested: RET (NM_020975)

Hotline History

N/A

CPT Codes

81406

Components

Component Test Code* Component Chart Name LOINC
3004573 MEN2 Specimen 31208-2
3004574 MEN2 Interp
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • familial medullary thyroid cancer (FMTC)
  • MEN2A
  • MEN2B
Multiple Endocrine Neoplasia Type 2 (MEN2), RET Sequencing